Skip to main content
. 2024 Jul 12;103(28):e38911. doi: 10.1097/MD.0000000000038911

Figure 1.

Figure 1.

Illustration of the patient disease regression during T-DXd and progression after switching to other agents. T-Dxd = Trastuzumab Deruxtecan.